API makers are looking for ways to slash costs and improve efficiencies to counter the impact currency fluctuations and other market challenges, earnings results from Lonza and BASF show.
Lonza has reported higher revenues and profits for H1 2015, but warned that the strength of the Swiss franc means its Visp facility is still finding it hard to compete.
The strengthening US Dollar will reduce CRO revenues, say analysts, but firms which have global strategic deals could benefit from reduced operational costs.
The value of the Swiss franc fluctuated today after the country’s central bank abandoned its minimum Euro exchange rate in a shock move that saw shares in Roche, Novartis, Actelion, SGS and Lonza fall.
Filtration and processing tech firm Pall Life Sciences’ biopharmaceutical business made the biggest contribution to its revenues revenues in fiscal Q2.
Patheon has posted a 12 per cent growth in operating profit in the second quarter and said there is “strong evidence” the business environment is improving.
Patheon says a slowdown in “outsourcing decision making,” manufacturing problems in Puerto Rico and cost related to JLL’s takeover bid hurt it in fiscal 09.
Revenues from Pall’s biopharmaceuticals division grew in fiscal 2009, excluding foreign currency changes, with the company benefiting from the “thriving market” for vaccines and expanding adoption of single-use systems.
Patheon has posted “disappointing” Q3 results, with manufacturing difficulties in Puerto Rico, a slowdown in demand for development services and reduced client demand for some products impacting on revenues.
Cambrex has posted a positive set of Q2 results, recording an operating income of $9m (€6.3m), but warned that the second half of the year is likely to be down on the corresponding six months of last year.
Patheon chief Wes Wheeler says the drop in Q1 losses the firm recently reported is due to the “restructuring activities and rigorous cost containment efforts” it enacted towards the end of last year.
Cincinatti, US-based clinical research organization Kendle has cut back its revenue expectations for 2008, primarily as a result of the strengthening of the US dollar, in common with some of its peers in the CRO sector.
Contract development and manufacturing company Patheon received an unsolicited takeover bid from private equity firm JLL Partners ahead of reporting a return to profit in its fiscal fourth quarter results.
Contract research organisation Parexel posted a 26 per cent hike in first quarter revenues to $263m but still failed to meet its own internal sales targets and saw net profits slide.
The Hovione Group revealed its yearly figures for 2005, which
revealed that sales grew by 8 per cent. The company's performance
is in contrast to the pharma fine chemicals sector, which between
2002 and 2004 had an average 14...
Yesterday, German chemicals group Degussa said that it had got off
to a good start financially in 2004. Today, the company provided a
more detailed breakdown of the first-quarter results which shows
the fine chemicals division still...
DSM has said it expects 'clearly higher' net profit from ordinary
operations in 2004, after reporting an unexpected increase in
first-quarter operating earnings.
Switzerland's Tecan saw its sales last year fall 6 per cent as
turnover growth in its genomics/proteomics division failed to
counterbalance declines in drug discovery and diagnostics.
DSM of the Netherlands saw its operating profit slump 23 per cent
to €294 million last year, hit by higher raw material costs and
declining sales of its life sciences products.
Danish company Chr Hansen saw its revenues slip 4 per cent in its
first quarter, as the impact of the economic downturn and tough
dollar exchange rate was felt across its business units.
Switzerland's Bachem saw its 2003 sales slip by 3 per cent as
continued slack demand for research chemicals held back a modest
increase in its active pharmaceutical ingredients business.
Filtration and purification specialist Pall has reported a 12.5 per
cent hike in first-quarter sales to $374 million (€310m), with life
sciences putting in a strong showing, up 15.5 per cent to $152
million.
DSM reports a disappointing set of second quarter results and says
it is unlikely to meet its 2002 operating profit level this year;
the group blames weaker demand for its products and negative
currency factors. Restructuring drive...
Tecan second-quarter results reveal some signs of recovery after a
torrid first quarter and the departure of former chief executive
Emile Sutcliffe, with diagnostics holding back an improved
performance in biopharma.
Switzerland's Bachem SA, which specialises in the manufacture and
sale of bulk peptides and related organic chemicals as active
ingredients for the pharmaceutical industry, has announced that it
expects full-year sales growth...
The global economic downturn marked 2003 first quarter results for
Dutch based life science company DSM but strong autonomous volume
growth boosted figures to higher than 2002.
